Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2014 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2014 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2014 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2014 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2014 19
2.4.1 Actavis to Acquire Allergan for USD66 Billion 19
2.4.2 Medtronic Raises USD17 Billion in Private Placement of Notes 20
2.4.3 Merck Acquires Cubist Pharma for USD9.5 Billion 20
2.4.4 Bayer Raises USD7 Billion in Public Offering Bonds 21
2.4.5 LabCorp to Acquire Covance for USD6.1 Billion 21
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2014 23
3.1.1 Top M&A Deals in Q4 2014 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2013 - Q4 2014 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2014 26
3.2.1 Top Initial Public Offerings in Q4 2014 27
3.2.2 Top Secondary Offerings in Q4 2014 28
3.2.3 Top PIPE Deals in Q4 2014 28
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2013-Q4 2014 29
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2013 - Q4 2014 29
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2014 31
3.3.1 Top Venture Financing Deals in Q4 2014 32
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2014 33
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2014 34
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2013 - Q4 2014 35
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2013 - Q4 2014 36
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2013 - Q4 2014 37
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2014 38
3.4.1 Top Private Equity Deals in Q4 2014 39
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2013 - Q4 2014 40
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2014 42
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2014 42
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2013 - Q4 2014 44
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 46
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2014 47
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2014 48
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2014 48
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 49
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2013 - Q4 2014 51
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2013 - Q4 2014 52
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 53
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2014 55
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2014 55
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 57
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2014 58
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2014 59
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2014 60
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2013 - Q4 2014 61
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2013 - Q4 2014 63
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2013 - Q4 2014 65
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2013 - Q4 2014 66
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2013 - Q4 2014 68
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 70
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2013 - Q4 2014 70
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2013 - Q4 2014 72
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2013 - Q4 2014 73
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2013 - Q4 2014 75
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2013 - Q4 2014 77
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2013 - Q4 2014 78
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2013 - Q4 2014 79
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 80
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2014 80
7.1.1 Oncology - Deals of the Quarter 82
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2014 84
7.2.1 Central Nervous System - Deals of the Quarter 86
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2014 88
7.3.1 Infectious Disease - Deals of the Quarter 89
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2014 92
7.4.1 Immunology - Deals of the Quarter 94
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2014 96
7.5.1 Metabolic Disorders - Deals of the Quarter 97
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2014 100
7.6.1 Cardiovascular - Deals of the Quarter 101
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2014 103
7.7.1 Gastrointestinal - Deals of the Quarter 104
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2014 106
7.8.1 Dermatology - Deals of the Quarter 107
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2014 109
7.9.1 Respiratory - Deals of the Quarter 110
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2014 113
7.10.1 Ophthalmology - Deals of the Quarter 114
8 Deal Summary by Geography 117
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2014 117
8.1.1 North America - Deals of the Quarter 119
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2014 121
8.2.1 Europe - Deals of the Quarter 122
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2014 126
8.3.1 Asia-Pacific - Deals of the Quarter 127
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2014 129
8.4.1 Rest of the World - Deals of the Quarter 130
9 Pharmaceuticals & Healthcare, Global, Top Advisors 132
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2013 - Q4 2014 132
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2013 - Q4 2014 134
10 Appendix 136
11 Further Information 139
11.1 Methodology 139
11.2 About GlobalData 140
11.3 Disclosure information 141
11.4 Disclaimer 141

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 16
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2014 18
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2014 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 24
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2014 24
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2013 - Q4 2014 25
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 27
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2014 27
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2014 28
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2014 28
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2013-Q4 2014 29
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2014 32
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2014 34
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 35
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 36
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2013 - Q4 2014 37
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 39
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2014 39
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 43
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 45
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 47
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 47
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2014 48
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2014 48
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 50
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2013 - Q4 2014 52
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 54
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 56
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 58
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2014 58
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2014 59
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2014 60
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 62
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2013 - Q4 2014 64
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2013 - Q4 2014 67
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 69
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2013 - Q4 2014 71
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2013 - Q4 2014 72
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2013 - Q4 2014 74
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2013 - Q4 2014 76
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2013 - Q4 2014 77
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2013 - Q4 2014 78
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2013 - Q4 2014 79
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 81
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 85
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 89
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 93
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 97
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 101
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 104
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 107
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 110
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 114
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 118
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 122
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 127
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 130
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 133
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 135
Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q4 2013-Q4 2014 136

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2014 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2014 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2013 - Q4 2014 23
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2013 - Q4 2014 25
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 26
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2013 - Q4 2014 29
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 31
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2014 33
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2014 34
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2013 - Q4 2014 35
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 36
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 38
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2013 - Q4 2014 40
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 42
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 44
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 46
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 49
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2013 - Q4 2014 51
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2013 - Q4 2014 52
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2013 - Q4 2014 53
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 61
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 63
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2013 - Q4 2014 65
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2013 - Q4 2014 66
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 - Q4 2014 68
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2013 - Q4 2014 70
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2013 - Q4 2014 72
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2013 - Q4 2014 73
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2013 - Q4 2014 75
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2013 - Q4 2014 77
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2013 - Q4 2014 78
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2013 - Q4 2014 79
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 80
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 84
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 88
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 92
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 96
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 100
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 103
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 106
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 109
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 113
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 117
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 121
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 126
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 129
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 132
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2013 - Q4 2014 134